The stock will trade on pipeline catalysts, not quarterly financials. Key binary event is the mid-2026 monotherapy data update for MICVO in 2L+ HNSCC, which will determine whether the dose-cap strategy preserves efficacy while improving safety. Cash runway into Q4 2026 provides ~2 quarters of operating visibility post-data — a positive readout could trigger financing, while a negative one would raise survival risk. Monitor for any early look at the data via abstract releases or investor events.
Price Chart
Executive Summary
Pyxis Oncology reported Q1 2026 financial results, with a net loss of $23.3M ($0.37/share) vs $21.2M ($0.35/share) in Q1 2025, reflecting increased R&D spending on its lead ADC candidate MICVO. The company completed target enrollment in the Phase 1 monotherapy expansion study and remains on track for key mid-2026 and 2H26 data readouts. Cash runway extends into Q4 2026, but the cash burn rate accelerated, with cash and investments declining from $68.3M (Dec 2025) to $42.5M (Mar 2026).
Key Financial Metrics
Key Facts
- Net loss of $23.3M ($0.37/share) for Q1 2026 vs $21.2M ($0.35/share) in Q1 2025
- Cash, cash equivalents, restricted cash, and short-term investments of $42.5M as of March 31, 2026, down from $68.3M at Dec 31, 2025
- R&D expenses increased to $20.0M from $17.0M YoY, driven by clinical trial costs for MICVO
- Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in Q1 2026
- Updated monotherapy data on track for mid-2026; updated combination data with pembrolizumab on track for 2H26
- Appointed Nelson Azoulay as Chief Business Officer in May 2026
- Cash runway expected into Q4 2026
Financial Impact
Net loss widened by $2.1M YoY; cash burn of ~$25.8M in Q1 2026
Risk Factors
- Cash runway only into Q4 2026 — financing risk if data disappoints or enrollment slows
- Phase 1 monotherapy data in mid-2026 is binary: dose-cap strategy may reduce efficacy vs the 46% ORR seen in the preliminary December 2025 dataset
- Single-asset clinical-stage biotech — any safety or efficacy signal failure would be value-destructive
- No revenue from product sales — fully dependent on non-dilutive funding and capital markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222818 |
| Document: pyxs-20260514.htm | 0001193125-26-222818 |
| Document: 0001193125-26-222818-index-headers.html | 0001193125-26-222818 |
| Document: 0001193125-26-222818-index.html | 0001193125-26-222818 |
| Document: 0001193125-26-222818.txt | 0001193125-26-222818 |
| 8-K Data (Synthetic) | 0001193125-26-222818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.14 (−36.69%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.14 (−44.99%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.14 (+33.75%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.14 (−28.90%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.14 (−18.63%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.14 (−24.91%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.14 (−28.90%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.14 (−3.17%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.14 (−3.17%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.14 (+25.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access